Clinical Trial Update: Thromboxane Receptor Antagonist to Improve Endothelial Function [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a thromboxane receptor antagonist for improving endothelial function in cardiovascular disease was completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Thromboxane receptor antagonist (thromboxane receptor antagonist)

Snippet

Sponsor: Jeffrey Rade | Conditions: Cardiovascular Diseases, Vascular Dilation | Phase 2 | Status: COMPLETED | Results posted: 2024-12-05